Repositioning Candidate Details
| Candidate ID: | R0432 |
| Source ID: | DB01169 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Arsenic trioxide |
| Synonyms: | Arsenic oxide; Arsenic trioxide; Arsenic(III) oxide; Arsenolite; Arsenous oxide; Arsenous oxide anhydride; Diarsenic oxide; Diarsenic trioxide; White arsenic |
| Molecular Formula: | As2O3 |
| SMILES: | O=[As]O[As]=O |
| Structure: |
|
| DrugBank Description: | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. |
| CAS Number: | 1327-53-3 |
| Molecular Weight: | 197.84 |
| DrugBank Indication: | For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression |
| DrugBank Pharmacology: | Arsenic Trioxide is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy. |
| DrugBank MoA: | The mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells <i>in vitro</i>. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis. |
| Targets: | Inhibitor of nuclear factor kappa-B kinase subunit beta inducer; Thioredoxin reductase 1, cytoplasmic inhibitor; Transcription factor AP-1 inducer; G1/S-specific cyclin-D1 antagonist; Mitogen-activated protein kinase 3 inducer; Mitogen-activated protein kinase 1 inducer; RAC-alpha serine/threonine-protein kinase inducer; Cyclin-dependent kinase inhibitor 1; Histone deacetylase 1; Protein PML |
| Inclusion Criteria: | Therapeutic strategy associated |
